Saturday, 31 October 2026European Markets

IDEX BIOMETRICS Stock 11.71% Up On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with IDEX BIOMETRICS (IDEX.OL) jumping 11.71% to kr0.20 on Thursday while Oslo Børs Benchmark Index_GI jumped 0.76% to kr1,411.02.

IDEX BIOMETRICS's last close was kr0.18, 94.4% below its 52-week high of kr3.23.

About IDEX BIOMETRICS

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless smart cards, that includes financial payment and access control cards, as well as card-based devices for the storage of digital currencies. It primarily serves smart card manufacturers and similar solution integrators. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-1.06.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -217.51%.

Volatility

IDEX BIOMETRICS's last week, last month's, and last quarter's current intraday variation average was a negative 9.25%, a negative 7.94%, and a positive 6.24%.

IDEX BIOMETRICS's highest amplitude of average volatility was 9.25% (last week), 11.88% (last month), and 6.24% (last quarter).

Volume

Today's last reported volume for IDEX BIOMETRICS is 5276910 which is 41.15% above its average volume of 3738390.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IDEX BIOMETRICS's stock is considered to be overbought (>=80).

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com